The Global Tysabri (natalizumab) Drug Market was valued at USD 2.1 Billion in 2024 and is projected to reach USD 3.4 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period (2024–2030). This growth is being driven by the rising prevalence of multiple sclerosis and Crohn’s disease, increased adoption of high-efficacy therapies, and significant advancements in patient monitoring and risk management protocols for Progressive Multifocal Leukoencephalopathy (PML).

As the treatment landscape for neuroinflammatory diseases evolves toward personalized medicine and improved safety profiles, the spotlight is on the key pharmaceutical companies driving innovation, clinical research, and patient access. In this blog, we profile the Top 10 Companies in the Tysabri (natalizumab) Drug Industry—a mix of originators, biosimilar developers, and specialty pharma leaders shaping the future of global multiple sclerosis care.

Download FREE Sample Report: Tysabri (natalizumab) Drug Market – View in Detailed Research Report

---

🔟 1. Biogen Inc.

Headquarters: Cambridge, Massachusetts, USA
Key Offering: Tysabri (natalizumab) – Originator Product

Biogen is the originator and global leader in the Tysabri market, holding the exclusive rights to develop, manufacture, and commercialize natalizumab. The company has pioneered risk evaluation and mitigation strategies (REMS), including the TOUCH® Prescribing Program, to ensure safe use given the associated PML risk.

Innovation and Development Focus:

• Ongoing clinical trials for extended-interval dosing (EID) to reduce PML risk
• Investment in subcutaneous formulation development for patient convenience
• Global expansion of patient support and educational programs

Download FREE Sample Report: Tysabri (natalizumab) Drug Market – View in Detailed Research Report

---

9️⃣ 2. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Sandoz (biosimilar division), Gilenya (competing oral DMT)

While not a direct marketer of natalizumab, Novartis is a formidable player in the multiple sclerosis space through its Sandoz biosimilars division and its own portfolio of disease-modifying therapies (DMTs). Sandoz is strategically positioned to enter the natalizumab biosimilar market upon patent expiry, leveraging its extensive global manufacturing and commercialization capabilities.

Strategic Initiatives:

• Extensive pipeline of biosimilars for immunology and neurology
• Strong R&D focus on next-generation MS therapies

---

8️⃣ 3. Roche Holding AG

Headquarters: Basel, Switzerland
Key Offering: Ocrevus (ocrelizumab), Competing high-efficacy DMT

Roche is a key competitor in the high-efficacy MS treatment segment with Ocrevus. Its deep expertise in monoclonal antibodies and neurology provides a strong foundation for potential future interest in the natalizumab space, either through partnership or acquisition, especially as treatment paradigms evolve.

Strategic Initiatives:

• Leadership in B-cell therapy for MS
• Advanced diagnostics for biomarker identification and patient stratification

---

7️⃣ 4. Teva Pharmaceutical Industries Ltd.

Headquarters: Tel Aviv, Israel
Key Offering: Copaxone (glatiramer acetate), Austedo, Biosimilar pipeline

Teva, with its significant presence in the CNS and MS markets, is actively developing a portfolio of biosimilars. The company’s established commercial infrastructure for specialty drugs positions it as a potential future competitor for a natalizumab biosimilar, aiming to increase patient access and affordability.

Strategic Initiatives:

• Investment in complex generic and biosimilar pipelines
• Strategic partnerships to enhance global biosimilar reach

---

6️⃣ 5. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Mavenclad (cladribine)

Merck KGaA holds a significant position in the MS market with its short-course oral treatment, Mavenclad. The company’s strong global footprint and R&D capabilities in neurology make it a notable entity in the competitive landscape surrounding high-efficacy therapies like Tysabri.

Strategic Initiatives:

• Focus on immune reconstitution therapies as an alternative to continuous immunosuppression
• Expanding real-world evidence generation for its MS portfolio

Download FREE Sample Report: Tysabri (natalizumab) Drug Market – View in Detailed Research Report

---

5️⃣ 6. Sanofi

Headquarters: Paris, France
Key Offering: Aubagio (teriflunomide), Lemtrada (alemtuzumab)

Sanofi competes in the MS arena with both moderate and high-efficacy therapies. The company’s acquisition and integration strategies, along with its vast vaccine and immunology experience, provide a platform that could support future ventures into the monoclonal antibody space, including potential interest in natalizumab’s market segment.

Strategic Initiatives:

• Portfolio optimization in specialty care, including neurology
• Exploration of combination therapies and new mechanistic approaches

---

4️⃣ 7. Bristol Myers Squibb

Headquarters: New York, New York, USA
Key Offering: Zeposia (ozanimod)

Following its acquisition of Celgene, Bristol Myers Squibb entered the MS market with Zeposia. The company’s robust immuno-inflammation pipeline and expertise in managing complex therapies position it as an influential player whose strategies can impact the competitive dynamics for drugs like Tysabri.

Strategic Initiatives:

• Leveraging immunology expertise from other therapeutic areas for neurology
• Focus on oral therapies with differentiated safety profiles

---

3️⃣ 8. Johnson & Johnson (Janssen Pharmaceuticals)

Headquarters: New Brunswick, New Jersey, USA
Key Offering: Ponvory (ponesimod)

Johnson & Johnson’s Janssen division has built a presence in immunology and has recently entered the MS market. Its massive R&D budget and global commercial reach make it a company to watch, capable of influencing treatment guidelines and market access for all MS therapies, including natalizumab.

Strategic Initiatives:

• Expansion into neuroimmunology and other neurological disorders
• Utilization of big data and predictive analytics for therapy optimization

---

2️⃣ 9. Pfizer Inc.

Headquarters: New York, New York, USA
Key Offering: Biosimilar pipeline through Centus (joint venture)

Pfizer is a global powerhouse in both innovative medicines and biosimilars. Through its joint venture and internal programs, Pfizer has the capability to develop and commercialize a natalizumab biosimilar, potentially increasing market competition and accessibility post-patent expiration.

Strategic Initiatives:

• Aggressive investment in biosimilar development and manufacturing
• Global regulatory expertise for bringing complex biologics to market

---

1️⃣ 10. Viatris Inc.

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Broad portfolio of generics and biosimilars

Formed from the merger of Mylan and Upjohn, Viatris is focused on expanding access to medicines worldwide. The company’s strategic intent in the biosimilars space marks it as a potential future entrant into the natalizumab market, aiming to provide cost-effective alternatives in both developed and emerging economies.

Strategic Initiatives:

• Building a leading global biosimilar portfolio
• Focus on enhancing supply chain resilience for complex injectables

Get Full Report Here: Tysabri (natalizumab) Drug Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Tysabri is Smarter and Safer

The Tysabri (natalizumab) drug market is undergoing a significant transformation. While the originator product continues to demonstrate strong efficacy, the industry is investing heavily in risk mitigation strategies, alternative formulations, and preparing for the eventual patent cliff that will open the door to biosimilar competition.

📈 Key Trends Shaping the Market:

• Advancement and validation of Extended Interval Dosing (EID) to enhance patient safety
• Intensifying R&D into subcutaneous formulations for improved convenience
• Growing preparedness for biosimilar market entry post-2025
• Increased integration of JCV antibody testing and biomarker-driven treatment decisions

Get Full Report Here: Tysabri (natalizumab) Drug Market – View in Detailed Research Report

The companies listed above are not only providing critical therapies for neuroinflammatory diseases—they’re spearheading the evolution toward more personalized and safer treatment paradigms for patients worldwide.